Not exact matches
Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability
of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost
of accommodating, announced increases in the build
rates of certain aircraft; 6) the effect on aircraft demand and build
rates of changing customer preferences for business aircraft, including the effect
of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result
of global economic uncertainty or otherwise; 8) the effect
of economic conditions in the industries and markets in which we operate in the U.S. and globally and any
changes therein, including fluctuations in foreign currency exchange
rates; 9) the success and timely execution
of key milestones such as the receipt
of necessary regulatory
approvals, including our ability to obtain in a timely fashion any required regulatory or other third party
approvals for the consummation
of our announced acquisition
of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability
of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk
of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production
of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts
of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak
of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact
of future discount
rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition
of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect
of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect
of changes in tax law, such as the effect
of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and
changes to the interpretations
of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect
of such
changes; 21) any reduction in our credit
ratings; 22) our dependence on our suppliers, as well as the cost and availability
of raw materials and purchased components; 23) our ability to recruit and retain a critical mass
of highly - skilled employees and our relationships with the unions representing many
of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment
of interest on, and principal
of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest
rates increase substantially; 27) the effectiveness
of any interest
rate hedging programs; 28) the effectiveness
of our internal control over financial reporting; 29) the outcome or impact
of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition
of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse
changes to business relationships and other business disruptions for ourselves and Asco as a result
of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks
of doing business internationally, including fluctuations in foreign current exchange
rates, impositions
of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
Such factors include, among others, general business, economic, competitive, political and social uncertainties; the actual results
of current and future exploration activities; the actual results
of reclamation activities; conclusions
of economic evaluations; meeting various expected cost estimates;
changes in project parameters and / or economic assessments as plans continue to be refined; future prices
of metals; possible variations
of mineral grade or recovery
rates; the risk that actual costs may exceed estimated costs; failure
of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks
of the mining industry; political instability; delays in obtaining governmental
approvals or financing or in the completion
of development or construction activities, as well as those factors discussed in the section entitled «Risk Factors» in the Company's Annual Information Form for the year ended December 31, 2017 dated March 15, 2018.
Such risks, uncertainties and other factors include, without limitation: (1) the effect
of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any
changes therein, including financial market conditions, fluctuations in commodity prices, interest
rates and foreign currency exchange
rates, levels
of end market demand in construction and in both the commercial and defense segments
of the aerospace industry, levels
of air travel, financial condition
of commercial airlines, the impact
of weather conditions and natural disasters and the financial condition
of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization
of the anticipated benefits
of advanced technologies and new products and services; (3) the scope, nature, impact or timing
of acquisition and divestiture or restructuring activity, including the pending acquisition
of Rockwell Collins, including among other things integration
of acquired businesses into United Technologies» existing businesses and realization
of synergies and opportunities for growth and innovation; (4) future timing and levels
of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability
of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope
of future repurchases
of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level
of other investing activities and uses
of cash, including in connection with the proposed acquisition
of Rockwell; (7) delays and disruption in delivery
of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits
of organizational
changes; (11) the anticipated benefits
of diversification and balance
of operations across product lines, regions and industries; (12) the outcome
of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact
of the negotiation
of collective bargaining agreements and labor disputes; (15) the effect
of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect
of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange
rates in the near term and beyond; (16) the effect
of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act
of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability
of United Technologies and Rockwell Collins to receive the required regulatory
approvals (and the risk that such
approvals may result in the imposition
of conditions that could adversely affect the combined company or the expected benefits
of the merger) and to satisfy the other conditions to the closing
of the pending acquisition on a timely basis or at all; (18) the occurrence
of events that may give rise to a right
of one or both
of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee
of $ 695 million to United Technologies or $ 50 million
of expense reimbursement; (19) negative effects
of the announcement or the completion
of the merger on the market price
of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation
of their businesses while the merger agreement is in effect; (21) risks relating to the value
of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability
of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory
approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to
changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange
rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Factors that could cause actual results to differ include general business and economic conditions and the state
of the solar industry; governmental support for the deployment
of solar power; future available supplies
of high - purity silicon; demand for end - use products by consumers and inventory levels
of such products in the supply chain;
changes in demand from significant customers;
changes in demand from major markets such as Japan, the U.S., India and China;
changes in customer order patterns;
changes in product mix; capacity utilization; level
of competition; pricing pressure and declines in average selling prices; delays in new product introduction; delays in utility - scale project
approval process; delays in utility - scale project construction; delays in the completion
of project sales; continued success in technological innovations and delivery
of products with the features customers demand; shortage in supply
of materials or capacity requirements; availability
of financing; exchange
rate fluctuations; litigation and other risks as described in the Company's SEC filings, including its annual report on Form 20 - F filed on April 27, 2017.
Factors that could cause actual results to differ include general business and economic conditions and the state
of the solar industry; governmental support for the deployment
of solar power; future available supplies
of high - purity silicon; demand for end - use products by consumers and inventory levels
of such products in the supply chain;
changes in demand from significant customers;
changes in demand from major markets such as Japan, the U.S., India and China;
changes in customer order patterns;
changes in product mix; capacity utilization; level
of competition; pricing pressure and declines in average selling prices; delays in new product introduction; delays in utility - scale project
approval process; delays in utility - scale project construction; continued success in technological innovations and delivery
of products with the features customers demand; shortage in supply
of materials or capacity requirements; availability
of financing; exchange
rate fluctuations; litigation and other risks as described in the Company's SEC filings, including its annual report on Form 20 - F filed on April 20, 2016.
Factors that could cause actual results to differ include general business and economic conditions and the state
of the solar industry; governmental support for the deployment
of solar power; future available supplies
of high - purity silicon; demand for end - use products by consumers and inventory levels
of such products in the supply chain;
changes in demand from significant customers;
changes in demand from major markets such as Japan, the U.S., India and China;
changes in customer order patterns;
changes in product mix; capacity utilization; level
of competition; pricing pressure and declines in average selling prices; delays in new product introduction; delays in utility - scale project
approval process; delays in utility - scale project construction; cancelation
of utility - scale feed - in - tariff contracts in Japan; continued success in technological innovations and delivery
of products with the features customers demand; shortage in supply
of materials or capacity requirements; availability
of financing; exchange
rate fluctuations; litigation and other risks as described in the Company's SEC filings, including its annual report on Form 20 - F filed on April 27, 2017.
We are seeking to require prior consent and
approval of any
changes made to the LIBOR or reference benchmark
rate in the final credit agreement as a condition
of investing.
Given the relationship between the level
of housing loan
approvals and the dollar - value movement in housing credit, it is possible to derive a relationship between the percentage
change in
approvals and the growth
rate of credit.
There is little
change in the job
approval ratings of U.S. Senators Charles Schumer and Kirsten Gillibrand.
The
changes from last September are predictable, given how the Lib Dem poll
ratings have continued to decline since then — Clegg's
approval rating is now at minus 29 compared to plus 8 a year ago, the proportion
of people who support the coalition agreement is down to 34 % from 43 % a year ago.
Meanwhile, the piece
of legislation that could have the greatest impact on rent that is being backed by advocates would
change the requirements for serving on the Rent Guidelines Board — the group that sets the
rates for rent - controlled apartments and give the City Council
approval over the Mayor's appointments to the body.
With the low
approval ratings of both the State Senate and Assembly, it's not surprising that voters think major
changes are needed in the way things are done in state government in Albany.
And it's true that the
change in voting intentions has been less dramatic - but nonetheless, as my colleague Roger Mortimore has pointed out, at this stage
of a parliament it can be just as useful to look at
approval ratings as voting intention.
This is little
changed from an April survey, when Cuomo was given a job
approval rating of 51 percent to 38 percent.
However Cuomo's
approval rating is relatively strong, at 57 %, and Greenberg says if the governor actually achieves ethics reform and some
of his more popular education
changes, the public is likely to back that.
«For Mayor Bloomberg, the
change is in his overall
approval rating, not in his handling
of the city budget, the direction
of the city, or how New Yorkers think they will remember his years in office,» says Dr. Lee M. Miringoff, Director
of The Marist College Institute for Public Opinion.
Approval ratings remain pretty much the same — there has been no further slump in government or Brown's
ratings (in fact Brown's dire net
rating of minus 45 is the best he's had for a couple
of months), not any real
change in Nick Clegg's
rating.
One possibly surprising aspect
of Oak Park's status report is that even during times
of intense accountability reform and
change, district employees gave high
approval ratings.
TABOR requires that the state and all school districts obtain advance voter
approval for any new tax, tax
rate increase, mill levy above that for the prior year, valuation for assessment ratio increase for a property class, extension
of an expiring tax, or tax policy
change directly causing a net tax revenue gain.
Upon election
of the A4 - 1 / A4 - 2 method
of determining tuition
rates, a regular school district must continue to utilize this methodology until such time as Commissioner
approval to
change back to the Commissioner's Report methodology is requested and received.
6.28.16 APPROVED Agenda
Approval of Minutes
Approval of 4/26/2016 Minutes President's Report ACES Project Update,
Change Orders Proposed TAS Board Meeting Calendar 2016 - 2017 Finance Committee Report Operating Budgets and Cash Flow 2016 - 2019 Financial Statement for 11 months ending May 31, 2016 Fiscal Policy and Procedures Handbook Staff Reports LAUSD Oversight
Ratings Summary TAS Responses to LAUSD Oversight
Ratings Summary Errors, Challenges to LAUSD Oversight ACES LCAP 2016 - 2019 TAS LCAP 2016 - 2019 WAHS LCAP 2016 - 2019 ACES SPSA 2016 - 2017 ACES SPSA Abbreviated 2016 - 2017 TAS K. 8 SPSA 2016 - 2017 TAS SPSA Abbreviated 2016 - 2017 WAHS SPSA 2016 - 2017 WAHS SPSA abbreviated 2016 - 2017 ACES 2016 - 2017 Calendar TAS - WAHS Calendar 2016 - 17 Curriculum Processes / Textbook Adoption Process Expulsion Readmission into Lottery Process
Moderate income home shoppers continue to enjoy the combined positive effects
of low interest
rates, lower home prices (although there are signs
of change), and flexible FHA guidelines for loan
approval.
Upon
approval of your application, your loan's Annual Percentage
Rate (APR) will be established and will not
change throughout the life
of your loan.
The higher your credit score, the higher your chance
of approval and the higher
change of getting the best personal loan
rates.
BIG ZERO advertised interest
rates are subject to
change without notice BIG ZERO loans are locked at time
of Underwriting
Approval and at no point in time prior.
Knowing what your score is and the reasons behind it are important so that you can make
changes before you apply for a mortgage — and increase your chances
of approval and a favorable mortgage
rate.
Any
change in amount or
rate of charges as stated above will be subject to IRDAI
approval.
Any
change in amount or
rate of charges as stated above will be subject to IRDA
approval.
The discount
rate can be revised by the Company after getting IRDAI's
approval on the basis
of changing investment returns.